Randomised phase 2 study of sapanisertib (TAK?228/MLN0128) ± TAK-117 versus everolimus in patients with VEGF-targeted therapy-refractory metastatic clear cell renal cell carcinoma

Randomised phase 2 study of sapanisertib (TAK?228/MLN0128) ± TAK-117 versus everolimus in patients with VEGF-targeted therapy-refractory metastatic clear cell renal cell carcinoma

User Photo
superboy

1 year
130 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Toni K. Choueiri MD of Dana Farber discusses Randomised phase 2 study of sapanisertib (TAK?228/MLN0128) ± TAK-117 versus everolimus in patients with VEGF-targeted therapy-refractory metastatic clear cell renal cell carcinoma at the Kidney Cancer Association International Symposium 2019 in Dubrovnik, Croatia
Up Next Autoplay
>